FDAFDA · Food and drugs·Recall number D-1143-2023
Nexlizet (bempedoic acid and ezetimibe), 180ng/18mg, 30 tablets, Rx only, Manufactured for: Esperion Therapeutics, Inc, Ann Arbor, MI 48108, NDC 72426-818-03
Published September 13, 2023 · Recall initiated: August 16, 2023
Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Failed dissolution specifications: below specification results at stability 12-month
What to do
Voluntary: Firm initiated · Letter
Recall details
- Brand
- NEXLIZET
- Manufacturer
- Esperion
- Distributor
- Nationwide USA
- Lot
- Lot# 1904872, Exp 1/31/2025; 1950377, Exp 6/30/2025
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Sell products like this?
Recalert watches your whole catalog for recalls like this one, automatically.